OBJECTIVE: To determine whether Ginkgo biloba extract (ginkgo) improves cognitive function in persons with multiple sclerosis (MS). METHODS:Persons with MS from the Seattle and Portland VA clinics and adjacent communities who scored 1 SD or more below the mean on one of 4neuropsychological tests (Stroop Test, California Verbal Learning Test II [CVLT-II], Controlled Oral Word Association Test [COWAT], and Paced Auditory Serial Addition Task [PASAT]) were randomly assigned to receive either one 120-mg tablet of ginkgo (EGb-761; Willmar Schwabe GmbH & Co, Germany) or one placebo tablet twice a day for 12 weeks. As the primary outcome, we compared the performance of the 2 groups on the 4 tests at exit after adjusting for baseline performance. RESULTS:Fifty-nine subjects receivedplacebo and 61 received ginkgo; 1 participant receiving placebo and 3 receiving ginkgo were lost to follow-up. Two serious adverse events (AEs) (myocardial infarction and severe depression) believed to be unrelated to the treatment occurred in the ginkgo group; otherwise, there were no significant differences in AEs. The differences (ginkgo - placebo) at exit in the z scores for the cognitive tests were as follows: PASAT -0.2 (95% confidence interval [CI] -0.5 to 0.1); Stroop Test -0.5 (95% CI -0.9 to -0.1); COWAT 0.0 (95% CI -0.2 to 0.3); and CVLT-II 0.0 (95% CI -0.3 to 0.3); none was statistically significant. CONCLUSIONS: Treatment with ginkgo 120 mg twice a day did not improve cognitive performance in persons with MS. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that treatment with ginkgo 120 mg twice a day for 12 weeks does not improve cognitive performance in people with MS.
RCT Entities:
OBJECTIVE: To determine whether Ginkgo biloba extract (ginkgo) improves cognitive function in persons with multiple sclerosis (MS). METHODS:Persons with MS from the Seattle and Portland VA clinics and adjacent communities who scored 1 SD or more below the mean on one of 4 neuropsychological tests (Stroop Test, California Verbal Learning Test II [CVLT-II], Controlled Oral Word Association Test [COWAT], and Paced Auditory Serial Addition Task [PASAT]) were randomly assigned to receive either one 120-mg tablet of ginkgo (EGb-761; Willmar Schwabe GmbH & Co, Germany) or one placebo tablet twice a day for 12 weeks. As the primary outcome, we compared the performance of the 2 groups on the 4 tests at exit after adjusting for baseline performance. RESULTS: Fifty-nine subjects received placebo and 61 received ginkgo; 1 participant receiving placebo and 3 receiving ginkgo were lost to follow-up. Two serious adverse events (AEs) (myocardial infarction and severe depression) believed to be unrelated to the treatment occurred in the ginkgo group; otherwise, there were no significant differences in AEs. The differences (ginkgo - placebo) at exit in the z scores for the cognitive tests were as follows: PASAT -0.2 (95% confidence interval [CI] -0.5 to 0.1); Stroop Test -0.5 (95% CI -0.9 to -0.1); COWAT 0.0 (95% CI -0.2 to 0.3); and CVLT-II 0.0 (95% CI -0.3 to 0.3); none was statistically significant. CONCLUSIONS: Treatment with ginkgo 120 mg twice a day did not improve cognitive performance in persons with MS. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that treatment with ginkgo 120 mg twice a day for 12 weeks does not improve cognitive performance in people with MS.
Authors: Ralph H B Benedict; Diane Cookfair; Rebecca Gavett; Mark Gunther; Frederick Munschauer; Neeta Garg; Bianca Weinstock-Guttman Journal: J Int Neuropsychol Soc Date: 2006-07 Impact factor: 2.892
Authors: J Lovera; B Bagert; K Smoot; C D Morris; R Frank; K Bogardus; K Wild; B Oken; R Whitham; D Bourdette Journal: Mult Scler Date: 2007-01-29 Impact factor: 6.312
Authors: Evert-Jan Kooi; Marloes Prins; Natasha Bajic; Jeroen A M Beliën; Wouter H Gerritsen; Jack van Horssen; Eleonora Aronica; Anne-Marie van Dam; Jeroen J M Hoozemans; Paul T Francis; Paul van der Valk; Jeroen J G Geurts Journal: Acta Neuropathol Date: 2011-06-21 Impact factor: 17.088
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422
Authors: John E Lewis; Jillian Poles; Delaney P Shaw; Elisa Karhu; Sher Ali Khan; Annabel E Lyons; Susana Barreiro Sacco; H Reginald McDaniel Journal: J Clin Transl Res Date: 2021-08-04
Authors: Francois H Jacques; Brian T Harel; Adrian J Schembri; Chantal Paquette; Brigitte Bilodeau; Pawel Kalinowski; Reshmi Roy Journal: Mult Scler J Exp Transl Clin Date: 2016-06-07
Authors: Zhuhong Zhang; Si Chen; Hu Mei; Jiekun Xuan; Xiaoqing Guo; Letha Couch; Vasily N Dobrovolsky; Lei Guo; Nan Mei Journal: Sci Rep Date: 2015-09-30 Impact factor: 4.379
Authors: Michelle H Cameron; Vanessa Peterson; Eilis A Boudreau; Ashley Downs; Jesus Lovera; Edward Kim; Garnett P McMillan; Aaron P Turner; Jodie K Haselkorn; Dennis Bourdette Journal: Mult Scler Int Date: 2014-03-05
Authors: Daniela R de Oliveira; Claudia R Zamberlam; Gizelda M Rêgo; Alberto Cavalheiro; Janete M Cerutti; Suzete M Cerutti Journal: Front Behav Neurosci Date: 2016-01-05 Impact factor: 3.558
Authors: Rosalind Kalb; Meghan Beier; Ralph Hb Benedict; Leigh Charvet; Kathleen Costello; Anthony Feinstein; Jeffrey Gingold; Yael Goverover; June Halper; Colleen Harris; Lori Kostich; Lauren Krupp; Ellen Lathi; Nicholas LaRocca; Ben Thrower; John DeLuca Journal: Mult Scler Date: 2018-10-10 Impact factor: 6.312